CIK 0001853816 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Dermata Therapeutics, Inc.
Sign in to watch- Ticker
- DRMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (858)-223-0882
- Business address
- 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO, CA, 92130
- Former names
- Dermata Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award | +170,068 | 292,631 | ||
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award · Series E Warrant (Right to Buy) | +1,360,544 | 1,360,544 | ||
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award · Series F Warrant (Right to Buy) | +1,360,544 | 1,360,544 | ||
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award · Series E Warrant (Right to Buy) | +170,068 | 170,068 | ||
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award · Series F Warrant (Right to Buy) | +170,068 | 170,068 | ||
| 2026-08-16 | PROEHL GERALD T PRESIDENT, CHAIRMAN, CEO | Grant or award · Pre-Funded Warrant (Right to Buy) | +1,360,544 | 1,360,544 | ||
| 2026-08-16 | Van Hoose Kyri K. SVP, CFO | Grant or award | +102,040 | 232,463 | ||
| 2026-08-16 | Van Hoose Kyri K. SVP, CFO | Grant or award · Series E Warrant (Right to Buy) | +102,040 | 102,040 | ||
| 2026-08-16 | Van Hoose Kyri K. SVP, CFO | Grant or award · Series F Warrant (Right to Buy) | +102,040 | 102,040 | ||
| 2026-06-16 | Scott Kathleen D. Director | Sale | −11 | $1.19 | $13 | 0 |
| 2026-02-17 | Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Purchase | +1,000 | $1.27 | $1K | 1,012 |
| 2026-01-02 | Bedoya-Toro Munera Maria E SVP, Regulatory Affairs | Grant or award · Stock Option (right to buy) | +9,000 | 9,000 | ||
| 2026-01-02 | HALE DAVID F Director | Grant or award · Stock Option (Right to Buy) | +2,500 | 2,500 | ||
| 2026-01-02 | Sandler Andrew Seth Director | Grant or award · Stock Option (Right to Buy) | +2,500 | 2,500 | ||
| 2026-01-02 | Van Hoose Kyri K. SVP, CFO | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 | ||
| 2026-01-02 | FISHER MARY Director | Grant or award · Stock Option (Right to Buy) | +2,500 | 2,500 | ||
| 2026-01-02 | WIERENGA WENDELL Director | Grant or award · Stock Option (Right to Buy) | +2,500 | 2,500 | ||
| 2026-01-02 | PROEHL GERALD T President, CEO and Chairman | Grant or award · Stock Option (right to buy) | +37,500 | 37,500 | ||
| 2026-01-02 | Scott Kathleen D. Director | Grant or award · Stock Option (Right to Buy) | +2,500 | 2,500 | ||
| 2026-01-02 | Nardo Christopher J. Senior VP, CDO | Grant or award · Stock Option (right to buy) | +18,000 | 18,000 |
Page 1 of 9 · 172 trades